TABLE 3.
Percentage of E. coli isolates with antimicrobial resistancea
| Antibiotic | % resistant E. coli isolates |
P value | |
|---|---|---|---|
| CA-APN (n = 287) | HCA-APN (n = 47) | ||
| Ampicillin | 73.4 | 91.5 | 0.006 |
| Amoxicillin-clavulanic acid | 22.4 | 53.2 | 0.001 |
| Piperacillin-tazobactam | 18.4 | 53.8 | 0.001 |
| Cefuroxime | 7.7 | 43.5 | <0.0001 |
| Cefotaxime | 4.3 | 32.6 | <0.0001 |
| Ertapenem | 0 | 6.4 | 0.003 |
| Imipenem | 0 | 0 | |
| Amikacin | 2.7 | 4.2 | 0.547 |
| Ciprofloxacin | 22.8 | 74.5 | <0.0001 |
| Co-trimoxazole | 34.5 | 58.7 | 0.003 |
| Fosfomycin | 1.2 | 10.8 | 0.006 |
a
The percentages of extended-spectrum β-lactamase-producing Enterobacteriaceae isolates recovered from the patients in the community-acquired acute pyelonephritis and health care-associated acute pyelonephritis groups were 4.2 and 31.9%, respectively (P < 0.001). Abbreviations: CA-APN, community-acquired acute pyelonephritis; HCA-APN, health care-associated acute pyelonephritis.